» Articles » PMID: 38004559

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2023 Nov 25
PMID 38004559
Authors
Affiliations
Soon will be listed here.
Abstract

Physiologically based pharmacokinetic (PBPK) modeling is an approach to predicting drug pharmacokinetics, using knowledge of the human physiology involved and drug physiochemical properties. This approach is useful when predicting drug pharmacokinetics in under-studied populations, such as pediatrics. PBPK modeling is a particularly important tool for dose optimization for the neonatal population, given that clinical trials rarely include this patient population. However, important knowledge gaps exist for neonates, resulting in uncertainty with the model predictions. This review aims to outline the sources of variability that should be considered with developing a neonatal PBPK model, the data that are currently available for the neonatal ontogeny, and lastly to highlight the data gaps where further research would be needed.

Citing Articles

Physiologically Based Pharmacokinetic Modeling to Assess the Impact of Pathophysiological Changes in Neonates: Strengths, Weaknesses, and Next Steps.

Allegaert K J Clin Pharmacol. 2024; 64(12):1606-1609.

PMID: 39404134 PMC: 11591397. DOI: 10.1002/jcph.6148.


Combining data on the bioavailability of midazolam and physiologically-based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny.

Johnson T, Batchelor H, Goelen J, Horniblow R, Dinh J CPT Pharmacometrics Syst Pharmacol. 2024; 13(9):1570-1581.

PMID: 38923249 PMC: 11533100. DOI: 10.1002/psp4.13192.

References
1.
Mollison P, VEALL N, CUTBUSH M . Red cell and plasma volume in newborn infants. Arch Dis Child. 1950; 25(123):242-53. PMC: 1988304. DOI: 10.1136/adc.25.123.242. View

2.
McNamara P, Alcorn J . Protein binding predictions in infants. AAPS PharmSci. 2002; 4(1):E4. PMC: 2751289. DOI: 10.1208/ps040104. View

3.
Miyagi S, Milne A, Coughtrie M, Collier A . Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. Drug Metab Dispos. 2012; 40(7):1321-7. PMC: 3382841. DOI: 10.1124/dmd.111.043752. View

4.
Yang D, Pearce R, Wang X, Gaedigk R, Wan Y, Yan B . Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol. 2008; 77(2):238-47. PMC: 2671154. DOI: 10.1016/j.bcp.2008.10.005. View

5.
Leakey J, HUME R, Burchell B . Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem J. 1987; 243(3):859-61. PMC: 1147936. DOI: 10.1042/bj2430859. View